Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RXL vs UCC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RXL Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)

RXL Overall Winner 6-Pillar Tally: RXL 0 – 0 UCC (6 Tie) Matrix Metrics: RXL 3 – 0 UCC

As of Nov 16, 2026, ProShares Ultra Health Care (RXL) is the stronger overall head-to-head candidate over ProShares Ultra Consumer Discretionary (UCC) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). RXL carries a Unified Composite Score of 40.0/100 (SELL) at $71.98 (N/M Forward P/E, N/A operating margin), whereas UCC carries 31.8/100 (SELL) at $46.68 (N/M Forward P/E, N/A operating margin).

  • Defensive Composite Rating Caution: Although RXL compares more favorably head-to-head, both RXL (40.0/100 SELL) and UCC (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RXL vs UCC
RXL NYSE Arca Head-to-Head Winner
ProShares Ultra Health Care
Institutional Equity
$71.98
-1.1% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.54β · 41% Vol
Unified Composite Score
40.0 / 100 SELL
Tech 18.0 Fund 30.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.8% over 20 days), RSI 63
RSI-14: 63.5 · SMA20: $69.59 · SMA50: $63.42
UCC NYSE Arca
ProShares Ultra Consumer Discretionary
Institutional Equity
$46.68
-3.2% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.19β · 52% Vol
Unified Composite Score
31.8 / 100 SELL
Tech 8.0 Fund 25.0 Flow 50.0 Mom 21.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 54.2 · SMA20: $46.59 · SMA50: $44.03

6-Pillar Scorecard Institutional Category Breakdown (RXL 0 – 0 UCC)

Columns: Metric · RXL · UCC
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 32.8% (<1st %ile) 41.0% (<1st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RXL (3) vs UCC (0)
Institutional Metric RXL UCC Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
89% ($43–$76) 40% ($40–$57) Stronger Trend RXL
Beta / 30D Volatility
Risk Regime
0.54β · 41% Vol 2.19β · 52% Vol Lower Realized Risk RXL
Unified Institutional Score
Composite Signal
40.0 / 100 (SELL) 31.8 / 100 (SELL) Higher Composite RXL
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RXL +3.2 pp
RXL: +12.08% · UCC: +8.88%
3M Horizon RXL +20.34 pp
RXL: +20.44% · UCC: +0.1%
6M Horizon RXL +63.05 pp
RXL: +60.84% · UCC: -2.21%
1Y Horizon RXL +47.93 pp
RXL: +41.97% · UCC: -5.96%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RXL vs UCC. Trailing 12-month operating profitability (RXL N/A vs UCC N/A) and valuation multiples (RXL N/M vs UCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

RXL ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
UCC ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RXL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 32.8%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RXL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UCC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UCC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RXL Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
UCC Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ RXL vs UCC Key Questions & Quantitative Answers

As of Nov 16, 2026, ProShares Ultra Health Care (RXL) is the stronger overall head-to-head candidate over ProShares Ultra Consumer Discretionary (UCC) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). RXL carries a Unified Composite Score of 40.0/100 (SELL) at $71.98 (N/M Forward P/E, N/A operating margin), whereas UCC carries 31.8/100 (SELL) at $46.68 (N/M Forward P/E, N/A operating margin). Defensive Composite Rating Caution: Although RXL compares more favorably head-to-head, both RXL (40.0/100 SELL) and UCC (31.8/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.

RXL and UCC split Growth & Scale metrics: RXL posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with UCC at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, RXL generates N/A in USD-normalized revenue versus N/A for UCC. In operating R&D and SG&A reinvestment, RXL deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UCC.

RXL and UCC trade at balanced relative valuation multiples. RXL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas UCC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RXL (N/A ROE) versus UCC (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, RXL carries 32.8% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.54β · 41% Vol realized risk). By comparison, UCC carries 41.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.19β · 52% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.